April 15, 2021 04:58 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal Elections: Video clip on Sitalkuchi incident goes viral | Karnataka reports 11,265 Covid cases, highest one-day spike this year | No decision to cut short Kumbh Mela: Officials | Delhi reports over 17000 fresh Covid cases setting a new single-day record | Rajasthan announces 12-hr daily Covid curfew from 6 pm to 6 am in all cities
Strand partners MSMF for translational lab

Strand partners MSMF for translational lab

India Blooms News Service | | 22 Apr 2014, 11:50 am
Bangalore, Apr 22 (IBNS): With the aim of making genomics-based diagnostics accessible and affordable for people in India, Strand Life Sciences Private Limited, a global life sciences & clinical genomics company headquartered in Bangalore, entered into a partnership with the Mazumdar-Shaw Medical Foundation (MSMF) to set up the Strand at Mazumdar-Shaw (SAMS) translational lab in the Mazumdar-Shaw Centre for Translational Research (MSCTR) located at Bangalore.

This is a major milestone towards enabling an ecosystem of personalized medical treatment for patients with cancer and other genetic diseases.

Based on statistics, nearly seven lakh Indians die of cancer every year, while over 10 lakh are newly diagnosed with some form of the disease.

According to the latest World Cancer Report from the World Health Organization (WHO), there are over 4.77 lakh men and 5.37 lakh women diagnosed with cancer in India in 2012 alone.

The scale of these challenges requires the Indian healthcare industry to use affordability as a driver of innovation.

“We believe this collaboration will help us foster innovation and encourage in-depth research in the genomics space and thereby provide better care for patients with cancer and other genetic diseases,” said Dr. Kiran Mazumdar-Shaw, CMD, Biocon.

Strand through its expertise will offer comprehensive genomic testing for cancer and other germline/hereditary conditions at highly affordable costs. In addition, the collaboration will also entail promoting research in the field of genomics, conducting medical and non-medical programs, seminars and talks shows, assisting clinicians and scientists in performing quality research, and towards making genomics research resources and data available to scientists.

Talking about this partnership, Dr Vijay Chandru, Chairman & CEO, Strand Life Sciences, said, “This partnership is recognition of our joint commitment to bringing best in class healthcare technologies closer to people in India at affordable costs."

"As part of the vision laid out in the partnership, Strand has developed an affordable Hereditary Breast Cancer Diagnostic Test that will cost significantly less than comparable tests available in the West and India. This is the first of many innovations that we will develop at the SAMS translational lab.”